Novartis Ag (NVS) Change in Account Payables (2022 - 2025)

Novartis Ag has reported Change in Account Payables for 4 years, with the latest figure at -$172.0 million in Q1 2025.

• Quarterly Change in Account Payables rose 57.95% year-over-year to -$172.0 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was -$637.0 million (changed N/A YoY) and the FY2017 annual result came in at $58.0 million, changed N/A from the prior year.
• Change in Account Payables advanced to -$172.0 million in Q1 2025 per NVS's latest filing, from -$409.0 million in the prior quarter.
• Over five years, Change in Account Payables peaked at $87.0 million in Q1 2023 and troughed at -$409.0 million in Q1 2024.
• A 4-year average of -$159.2 million and a median of -$157.5 million in 2022 frame the typical range for Change in Account Payables.
• The sharpest annual moves came in 2023 and 2024: Change in Account Payables soared 160.84% in 2023, then sank 570.11% in 2024.
• Over 4 years, Change in Account Payables stood at -$143.0 million in 2022, then jumped by 160.84% to $87.0 million in 2023, then tumbled by 570.11% to -$409.0 million in 2024, then surged by 57.95% to -$172.0 million in 2025.
• According to Business Quant data, Change in Account Payables over the past three periods registered -$172.0 million, -$409.0 million, and $87.0 million for Q1 2025, Q1 2024, and Q1 2023 respectively.